Oasmia Pharmaceutical AB, of Uppsala, Sweden, gained a Nasdaq listing and raised $9.3 million by offering 2.3 million American depositary shares (ADSs) at $4.06 apiece, below its earlier range of $4.70 to $6.70. The offering also included 1.1 million warrants with an exercise price of $4.06 per ADS. Oasmia, which also trades on the Nasdaq Stockholm exchange, develops new formulations of existing chemo drugs for use in humans and dogs.